img

Global Live Attenuated Influenza Vaccine (LAIV) Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Live Attenuated Influenza Vaccine (LAIV) Market Insights, Forecast to 2034

The global Live Attenuated Influenza Vaccine (LAIV) market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Live Attenuated Influenza Vaccine (LAIV) is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Live Attenuated Influenza Vaccine (LAIV) is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Live Attenuated Influenza Vaccine (LAIV) is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The global key manufacturers of Live Attenuated Influenza Vaccine (LAIV) include Sanofi Pasteur, AstraZeneca, CSL, Abbott, GlaxoSmithKline, Serum Institute, Fluenz Tetra, Cytiva and BioDiem, etc. In 2022, the global top five players had a share approximately % in terms of revenue.

Report Includes


This report presents an overview of global market for Live Attenuated Influenza Vaccine (LAIV), sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Live Attenuated Influenza Vaccine (LAIV), also provides the sales of main regions and countries. Highlights of the upcoming market potential for Live Attenuated Influenza Vaccine (LAIV), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Live Attenuated Influenza Vaccine (LAIV) sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2024. Identification of the major stakeholders in the global Live Attenuated Influenza Vaccine (LAIV) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2034. Evaluation and forecast the market size for Live Attenuated Influenza Vaccine (LAIV) sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Sanofi Pasteur, AstraZeneca, CSL, Abbott, GlaxoSmithKline, Serum Institute, Fluenz Tetra, Cytiva and BioDiem, etc.



By Company


Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology
Segment by Type
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine

Segment by Application


Hospital
Clinic
Public Health Agency
Other

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Live Attenuated Influenza Vaccine (LAIV) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3Detailed analysis of Live Attenuated Influenza Vaccine (LAIV) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8China by type, by application sales and revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live Attenuated Influenza Vaccine (LAIV) sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Study Coverage
1.1 Live Attenuated Influenza Vaccine (LAIV) Product Introduction
1.2 Market by Type
1.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Trivalent Flu Vaccine
1.2.3 Quadrivalent Flu Vaccine
1.3 Market by Application
1.3.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Public Health Agency
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales Estimates and Forecasts 2018-2034
2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region
2.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region: 2018 VS 2022 VS 2034
2.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2018-2024)
2.2.3 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2024-2034)
2.2.4 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2018-2034)
2.3 Global Live Attenuated Influenza Vaccine (LAIV) Sales Estimates and Forecasts 2018-2034
2.4 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
2.4.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region: 2018 VS 2022 VS 2034
2.4.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2018-2024)
2.4.3 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2024-2034)
2.4.4 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Manufacturers
3.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Manufacturers (2018-2024)
3.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Live Attenuated Influenza Vaccine (LAIV) in 2022
3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Manufacturers
3.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Manufacturers (2018-2024)
3.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Live Attenuated Influenza Vaccine (LAIV) Revenue in 2022
3.3 Global Key Players of Live Attenuated Influenza Vaccine (LAIV), Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Live Attenuated Influenza Vaccine (LAIV) Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Product Offered and Application
3.8 Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type
4.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Historical Sales by Type (2018-2024)
4.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Forecasted Sales by Type (2024-2034)
4.1.3 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2018-2034)
4.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type
4.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Historical Revenue by Type (2018-2024)
4.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Forecasted Revenue by Type (2024-2034)
4.2.3 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2018-2034)
4.3 Global Live Attenuated Influenza Vaccine (LAIV) Price by Type
4.3.1 Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2018-2024)
4.3.2 Global Live Attenuated Influenza Vaccine (LAIV) Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application
5.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Historical Sales by Application (2018-2024)
5.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Forecasted Sales by Application (2024-2034)
5.1.3 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2018-2034)
5.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application
5.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Historical Revenue by Application (2018-2024)
5.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Forecasted Revenue by Application (2024-2034)
5.2.3 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2018-2034)
5.3 Global Live Attenuated Influenza Vaccine (LAIV) Price by Application
5.3.1 Global Live Attenuated Influenza Vaccine (LAIV) Price by Application (2018-2024)
5.3.2 Global Live Attenuated Influenza Vaccine (LAIV) Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada Live Attenuated Influenza Vaccine (LAIV) Market Size by Type
6.1.1 US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2018-2034)
6.1.2 US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2018-2034)
6.2 US & Canada Live Attenuated Influenza Vaccine (LAIV) Market Size by Application
6.2.1 US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2018-2034)
6.2.2 US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2018-2034)
6.3 US & Canada Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
6.3.1 US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue by Country: 2018 VS 2022 VS 2034
6.3.2 US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2018-2034)
6.3.3 US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Type
7.1.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2018-2034)
7.1.2 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2018-2034)
7.2 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Application
7.2.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2018-2034)
7.2.2 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2018-2034)
7.3 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
7.3.1 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country: 2018 VS 2022 VS 2034
7.3.2 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2018-2034)
7.3.3 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Live Attenuated Influenza Vaccine (LAIV) Market Size
8.1.1 China Live Attenuated Influenza Vaccine (LAIV) Sales (2018-2034)
8.1.2 China Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034)
8.2 China Live Attenuated Influenza Vaccine (LAIV) Market Size by Application
8.2.1 China Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2018-2034)
8.2.2 China Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Live Attenuated Influenza Vaccine (LAIV) Market Size by Type
9.1.1 Asia Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2018-2034)
9.1.2 Asia Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2018-2034)
9.2 Asia Live Attenuated Influenza Vaccine (LAIV) Market Size by Application
9.2.1 Asia Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2018-2034)
9.2.2 Asia Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2018-2034)
9.3 Asia Live Attenuated Influenza Vaccine (LAIV) Sales by Region
9.3.1 Asia Live Attenuated Influenza Vaccine (LAIV) Revenue by Region: 2018 VS 2022 VS 2034
9.3.2 Asia Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2018-2034)
9.3.3 Asia Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Market Size by Type
10.1.1 Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Market Size by Application
10.2.1 Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Country
10.3.1 Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country: 2018 VS 2022 VS 2034
10.3.2 Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Sanofi Pasteur
11.1.1 Sanofi Pasteur Company Information
11.1.2 Sanofi Pasteur Overview
11.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi Pasteur Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Recent Developments
11.3 CSL
11.3.1 CSL Company Information
11.3.2 CSL Overview
11.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 CSL Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 CSL Recent Developments
11.4 Abbott
11.4.1 Abbott Company Information
11.4.2 Abbott Overview
11.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Abbott Recent Developments
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Information
11.5.2 GlaxoSmithKline Overview
11.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 GlaxoSmithKline Recent Developments
11.6 Serum Institute
11.6.1 Serum Institute Company Information
11.6.2 Serum Institute Overview
11.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Serum Institute Recent Developments
11.7 Fluenz Tetra
11.7.1 Fluenz Tetra Company Information
11.7.2 Fluenz Tetra Overview
11.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Fluenz Tetra Recent Developments
11.8 Cytiva
11.8.1 Cytiva Company Information
11.8.2 Cytiva Overview
11.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Cytiva Recent Developments
11.9 BioDiem
11.9.1 BioDiem Company Information
11.9.2 BioDiem Overview
11.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 BioDiem Recent Developments
11.10 FluMist
11.10.1 FluMist Company Information
11.10.2 FluMist Overview
11.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 FluMist Recent Developments
11.11 GSK
11.11.1 GSK Company Information
11.11.2 GSK Overview
11.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 GSK Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 GSK Recent Developments
11.12 ChangChun High & New Technology
11.12.1 ChangChun High & New Technology Company Information
11.12.2 ChangChun High & New Technology Overview
11.12.3 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 ChangChun High & New Technology Recent Developments
11.13 BCHT Biotechnology
11.13.1 BCHT Biotechnology Company Information
11.13.2 BCHT Biotechnology Overview
11.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 BCHT Biotechnology Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Live Attenuated Influenza Vaccine (LAIV) Industry Chain Analysis
12.2 Live Attenuated Influenza Vaccine (LAIV) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Live Attenuated Influenza Vaccine (LAIV) Production Mode & Process
12.4 Live Attenuated Influenza Vaccine (LAIV) Sales and Marketing
12.4.1 Live Attenuated Influenza Vaccine (LAIV) Sales Channels
12.4.2 Live Attenuated Influenza Vaccine (LAIV) Distributors
12.5 Live Attenuated Influenza Vaccine (LAIV) Customers
13 Market Dynamics
13.1 Live Attenuated Influenza Vaccine (LAIV) Industry Trends
13.2 Live Attenuated Influenza Vaccine (LAIV) Market Drivers
13.3 Live Attenuated Influenza Vaccine (LAIV) Market Challenges
13.4 Live Attenuated Influenza Vaccine (LAIV) Market Restraints
14 Key Findings in The Global Live Attenuated Influenza Vaccine (LAIV) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Trivalent Flu Vaccine
Table 3. Major Manufacturers of Quadrivalent Flu Vaccine
Table 4. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2024-2034) & (US$ Million)
Table 8. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2018-2024)
Table 9. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2024-2034)
Table 10. Global Live Attenuated Influenza Vaccine (LAIV) Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 11. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2018-2024) & (K Units)
Table 12. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2024-2034) & (K Units)
Table 13. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2018-2024)
Table 14. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2024-2034)
Table 15. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Live Attenuated Influenza Vaccine (LAIV) Sales Share by Manufacturers (2018-2024)
Table 17. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Live Attenuated Influenza Vaccine (LAIV), Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Live Attenuated Influenza Vaccine (LAIV) Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Live Attenuated Influenza Vaccine (LAIV) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Live Attenuated Influenza Vaccine (LAIV) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Influenza Vaccine (LAIV) as of 2022)
Table 23. Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Product Offered and Application
Table 25. Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2018-2024) & (K Units)
Table 28. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2024-2034) & (K Units)
Table 29. Global Live Attenuated Influenza Vaccine (LAIV) Sales Share by Type (2018-2024)
Table 30. Global Live Attenuated Influenza Vaccine (LAIV) Sales Share by Type (2024-2034)
Table 31. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Type (2018-2024)
Table 34. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Type (2024-2034)
Table 35. Live Attenuated Influenza Vaccine (LAIV) Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Live Attenuated Influenza Vaccine (LAIV) Price Forecast by Type (2024-2034) & (US$/Unit)
Table 37. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2018-2024) & (K Units)
Table 38. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2024-2034) & (K Units)
Table 39. Global Live Attenuated Influenza Vaccine (LAIV) Sales Share by Application (2018-2024)
Table 40. Global Live Attenuated Influenza Vaccine (LAIV) Sales Share by Application (2024-2034)
Table 41. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Application (2018-2024)
Table 44. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Application (2024-2034)
Table 45. Live Attenuated Influenza Vaccine (LAIV) Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Live Attenuated Influenza Vaccine (LAIV) Price Forecast by Application (2024-2034) & (US$/Unit)
Table 47. US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2024-2034) & (K Units)
Table 49. US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2024-2034) & (US$ Million)
Table 51. US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2024-2034) & (K Units)
Table 53. US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2024-2034) & (US$ Million)
Table 55. US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 56. US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2024-2034) & (US$ Million)
Table 58. US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2024-2034) & (K Units)
Table 60. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2018-2024) & (K Units)
Table 61. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2024-2034) & (K Units)
Table 62. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2024-2034) & (US$ Million)
Table 64. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2018-2024) & (K Units)
Table 65. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2024-2034) & (K Units)
Table 66. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2024-2034) & (US$ Million)
Table 68. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 69. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2024-2034) & (US$ Million)
Table 71. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2018-2024) & (K Units)
Table 72. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2024-2034) & (K Units)
Table 73. China Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2018-2024) & (K Units)
Table 74. China Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2024-2034) & (K Units)
Table 75. China Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2024-2034) & (US$ Million)
Table 77. China Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2018-2024) & (K Units)
Table 78. China Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2024-2034) & (K Units)
Table 79. China Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2024-2034) & (US$ Million)
Table 81. Asia Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2018-2024) & (K Units)
Table 82. Asia Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2024-2034) & (K Units)
Table 83. Asia Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2024-2034) & (US$ Million)
Table 85. Asia Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2018-2024) & (K Units)
Table 86. Asia Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2024-2034) & (K Units)
Table 87. Asia Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2024-2034) & (US$ Million)
Table 89. Asia Live Attenuated Influenza Vaccine (LAIV) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 90. Asia Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2024-2034) & (US$ Million)
Table 92. Asia Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2018-2024) & (K Units)
Table 93. Asia Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2024-2034) & (K Units)
Table 94. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2024-2034) & (K Units)
Table 96. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2024-2034) & (US$ Million)
Table 98. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2024-2034) & (K Units)
Table 100. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2024-2034) & (US$ Million)
Table 102. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 103. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2024-2034) & (US$ Million)
Table 105. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2024-2034) & (K Units)
Table 107. Sanofi Pasteur Company Information
Table 108. Sanofi Pasteur Description and Major Businesses
Table 109. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Sanofi Pasteur Recent Developments
Table 112. AstraZeneca Company Information
Table 113. AstraZeneca Description and Major Businesses
Table 114. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. AstraZeneca Recent Developments
Table 117. CSL Company Information
Table 118. CSL Description and Major Businesses
Table 119. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. CSL Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. CSL Recent Developments
Table 122. Abbott Company Information
Table 123. Abbott Description and Major Businesses
Table 124. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Abbott Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Abbott Recent Developments
Table 127. GlaxoSmithKline Company Information
Table 128. GlaxoSmithKline Description and Major Businesses
Table 129. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. GlaxoSmithKline Recent Developments
Table 132. Serum Institute Company Information
Table 133. Serum Institute Description and Major Businesses
Table 134. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Serum Institute Recent Developments
Table 137. Fluenz Tetra Company Information
Table 138. Fluenz Tetra Description and Major Businesses
Table 139. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Fluenz Tetra Recent Developments
Table 142. Cytiva Company Information
Table 143. Cytiva Description and Major Businesses
Table 144. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Cytiva Recent Developments
Table 147. BioDiem Company Information
Table 148. BioDiem Description and Major Businesses
Table 149. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. BioDiem Recent Developments
Table 152. FluMist Company Information
Table 153. FluMist Description and Major Businesses
Table 154. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. FluMist Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. FluMist Recent Developments
Table 157. GSK Company Information
Table 158. GSK Description and Major Businesses
Table 159. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. GSK Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. GSK Recent Developments
Table 162. ChangChun High & New Technology Company Information
Table 163. ChangChun High & New Technology Description and Major Businesses
Table 164. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 165. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. ChangChun High & New Technology Recent Developments
Table 167. BCHT Biotechnology Company Information
Table 168. BCHT Biotechnology Description and Major Businesses
Table 169. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 170. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. BCHT Biotechnology Recent Developments
Table 172. Key Raw Materials Lists
Table 173. Raw Materials Key Suppliers Lists
Table 174. Live Attenuated Influenza Vaccine (LAIV) Distributors List
Table 175. Live Attenuated Influenza Vaccine (LAIV) Customers List
Table 176. Live Attenuated Influenza Vaccine (LAIV) Market Trends
Table 177. Live Attenuated Influenza Vaccine (LAIV) Market Drivers
Table 178. Live Attenuated Influenza Vaccine (LAIV) Market Challenges
Table 179. Live Attenuated Influenza Vaccine (LAIV) Market Restraints
Table 180. Research Programs/Design for This Report
Table 181. Key Data Information from Secondary Sources
Table 182. Key Data Information from Primary Sources
List of Figures
Figure 1. Live Attenuated Influenza Vaccine (LAIV) Product Picture
Figure 2. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Type in 2022 & 2034
Figure 4. Trivalent Flu Vaccine Product Picture
Figure 5. Quadrivalent Flu Vaccine Product Picture
Figure 6. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Public Health Agency
Figure 11. Other
Figure 12. Live Attenuated Influenza Vaccine (LAIV) Report Years Considered
Figure 13. Global Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Live Attenuated Influenza Vaccine (LAIV) Revenue 2018-2034 (US$ Million)
Figure 15. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 16. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2018-2034)
Figure 17. Global Live Attenuated Influenza Vaccine (LAIV) Sales 2018-2034 ((K Units)
Figure 18. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2018-2034)
Figure 19. US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales YoY (2018-2034) & (K Units)
Figure 20. US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Live Attenuated Influenza Vaccine (LAIV) Sales YoY (2018-2034) & (K Units)
Figure 22. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Live Attenuated Influenza Vaccine (LAIV) Sales YoY (2018-2034) & (K Units)
Figure 24. China Live Attenuated Influenza Vaccine (LAIV) Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Asia (excluding China) Live Attenuated Influenza Vaccine (LAIV) Sales YoY (2018-2034) & (K Units)
Figure 26. Asia (excluding China) Live Attenuated Influenza Vaccine (LAIV) Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales YoY (2018-2034) & (K Units)
Figure 28. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Live Attenuated Influenza Vaccine (LAIV) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 30. The Top 5 and 10 Largest Manufacturers of Live Attenuated Influenza Vaccine (LAIV) in the World: Market Share by Live Attenuated Influenza Vaccine (LAIV) Revenue in 2022
Figure 31. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2018-2034)
Figure 33. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2018-2034)
Figure 34. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2018-2034)
Figure 35. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2018-2034)
Figure 36. US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2018-2034)
Figure 37. US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2018-2034)
Figure 38. US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2018-2034)
Figure 39. US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2018-2034)
Figure 40. US & Canada Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Country (2018-2034)
Figure 41. US & Canada Live Attenuated Influenza Vaccine (LAIV) Sales Share by Country (2018-2034)
Figure 42. U.S. Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 43. Canada Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 44. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2018-2034)
Figure 45. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2018-2034)
Figure 46. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2018-2034)
Figure 47. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2018-2034)
Figure 48. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Country (2018-2034)
Figure 49. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Share by Country (2018-2034)
Figure 50. Germany Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 51. France Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 52. U.K. Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 53. Italy Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 54. Russia Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 55. China Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2018-2034)
Figure 56. China Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2018-2034)
Figure 57. China Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2018-2034)
Figure 58. China Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2018-2034)
Figure 59. Asia Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2018-2034)
Figure 60. Asia Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2018-2034)
Figure 61. Asia Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2018-2034)
Figure 62. Asia Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2018-2034)
Figure 63. Asia Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Region (2018-2034)
Figure 64. Asia Live Attenuated Influenza Vaccine (LAIV) Sales Share by Region (2018-2034)
Figure 65. Japan Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 66. South Korea Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 67. China Taiwan Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 68. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 69. India Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 70. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2018-2034)
Figure 71. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2018-2034)
Figure 72. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2018-2034)
Figure 73. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2018-2034)
Figure 74. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Country (2018-2034)
Figure 75. Middle East, Africa and Latin America Live Attenuated Influenza Vaccine (LAIV) Sales Share by Country (2018-2034)
Figure 76. Brazil Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 77. Mexico Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 78. Turkey Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 79. Israel Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 80. GCC Countries Live Attenuated Influenza Vaccine (LAIV) Revenue (2018-2034) & (US$ Million)
Figure 81. Live Attenuated Influenza Vaccine (LAIV) Value Chain
Figure 82. Live Attenuated Influenza Vaccine (LAIV) Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed